Epigenetics: Current and future applications that are driving novel drug discovery

Date: August 22, 2010
Pages: 80
Price:
US$ 1,215.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EEA047F6635EN
Leaflet:

Download PDF Leaflet

Epigenetics: Current and future applications that are driving novel drug discovery
This new 75+ page August 2010 report provides a complete briefing on the emerging importance of epigenetic research in drug and diagnostic development
The Business Implications

CHAPTER 1 - EPIGENETICS DEFINED

Executive Summary
  Epigenetics defined

EPIGENETICS DE FINED
Epigenetic mechanisms
  DNA methylation
    Figure 1: Schematic showing the epigenetic mechanisms of DNA methylation and histone modification
  Chromatin remodelling and histone modifications
    Figure 2: Examples of covalent histone post-translational modifications
  Non-coding RNA
    Figure 3: miRNA processing pathway
Unravelling the power of epigenetics
EXPERT COMMENTARY: Professor Stephan Beck, University College London Cancer Institute
  Consortia for the study of epigenomics
  Which epigenomes and what to study?
  Applications of epigenomic data
New opportunities for biomarker discovery and drug targeting
  Conclusion and report outline

CHAPTER 2 - TECHNICAL CHALLENGES IN EPIGENETIC R&D

Executive Summary
  Technical challenges in epigenetic R&D

TECHNICAL CHALLENGES IN EPIGENETIC R&D
EXPERT COMMENTARY: Dr Chris Adams, Senior R&D Manager/Epigenetics, Life Technologies
Next generation sequencing
  Table 1: Platforms for next generation sequencing
  Table 2: Third generation sequencing platforms
DNA methylation
  Table 3: Methods for studying DNA methylation and their limitations
  Table 4: Suppliers of research tools for the study of DNA methylation
Chromatin structure and histone modifications
  Figure 4: Schematic of a chromatin immunoprecipitation experiment
  Table 5: Suppliers of research tools for the study of histone and chromatin modifications
microRNA
  Table 6: Suppliers of research tools for the study of miRNA
Conclusion

CHAPTER 3 - EPIGENETICS IN DRUG DISCOVERY & DEVELOPMENT

Executive Summary
  Epigenetics in drug discovery & development

EPIGENETICS IN DRUG DISCOVERY & DE VELOPMENT
Introduction
  Figure 5: Proteins involved in the modification of histones
  Figure 6: Number of drugs targeting epigenetic mechanisms by mechanism and stage of development
Epigenetics in cancer
  Epigenetic drug targets in cancer: DNA methyltransferases
    Table 7: Approved drugs targeting DNMTs
  Epigenetic drug targets in cancer: HDAC inhibitors
  Non-selective HDAC inhibitors
    Table 8: Pan-HDAC inhibitors in clinical development
EXPERT COMMENTARY: Dr Bernd Hentsch, Chief Development Officer, 4SC AG
Selective HDAC inhibitors
  Table 9: Selective HDAC inhibitors
EXPERT COMMENTARY: Dr David Simmons (CSO) & Dr Gitte Neubauer (VP Research Operations), Cellzome
Beyond DNMT and HDAC inhibition: New targets
  Table 10: Companies developing drugs for novel epigenetic targets
EXPERT COMMENTARY: Dr Robert Gould, CEO, Epizyme Inc
EXPERT COMMENTARY: Martin Bonde, CEO, EpiTherapeutics
Cancer the first frontier, where next?
  Table 11: Companies developing therapeutics for epigenetic mechanisms in diseases other than cancer
Non-coding RNAs
  Table 12: Companies developing therapeutic strategies related to miRNAs
  Table 13: Therapeutic areas for miRNA-based therapeutic discovery
EXPERT COMMENTARY: Dr. Andreas G. Bader, Associate Director of Research, Mirna Therapeutics, Inc.
The future

CHAPTER 4 - EPIGENETICS IN CLINICAL DIAGNOSTICS

Executive Summary
  Epigenetics in clinical diagnostics

EPIGENETICS IN CLINICAL DIAGNOSTICS
Introduction
DNA methylation patterns
  Table 14: Companies developing diagnostics to detect aberrant DNA methylation patterns
Epigenomics AG
  Figure 7: Epigenomics’ development programme
OncoMethylome Sciences
  Figure 8: OncoMethylome Sciences’ development programme
Orion Genomics
  Figure 9: Orion Genomics’ product development pipeline
Histone modifications
miRNAs
Rosetta Genomics
  Table 15: Approved and developmental diagnostic products from Rosetta Genomics
Asuragen Diagnostics
Exiqon A/S
  Table 16: Exiqon’s miRNA-based diagnostic pipeline
Biomarkers and personalised medicine
  Table 17: Diagnostic/pharma partnerships for epigenetic biomarker discovery
Outlook

CHAPTER 5 - PLAYERS, ALLIANCES & ACQUISITIONS

Executive Summary
Players, alliances & acquisitions

PLAYERS, ALLIANCES & ACQUISITIONS
Company activities at a glance – Therapeutics
  Table 18: Areas of focus for companies developing drugs for epigenetic targets
  4SC AG, Planegg-Martinsried, Germany
  Acetylon Pharmaceuticals Inc, Boston, MA
  Celgene Corporation, Summit, NJ
  Celleron Therapeutics, Oxon, UK
  Cellzome, Cambridge, UK, and Heidelberg, Germany
  Curis Inc, Cambridge MA
  Chroma Therapeutics Ltd, Oxon, UK
  Constellation Pharmaceuticals, Cambridge, MA
  EnVivo Pharmaceuticals, Watertown, MA
  EpiTherapeutics Aps, Copenhagen, Denmark
  Epizyme, Cambridge, MA
  MethylGene, Inc. Montreal, Quebec
  Mirna Therapeutics, Austin, TX
  miRagen Therapeutics, Boulder, CO
  Pharmacyclics, Sunnyvale, CA
  Progen Pharmaceuticals, Brisbane, Australia
  Regulus Therapeutics, Torrey Pines, CA
  Repligen Corporation, Waltham, MA
  Santaris Pharma A/S, Denmark
  SuperGen, Dublin, CA
  Syndax Pharmaceuticals, Waltham, MA
  TopoTarget, Copenhagen, Denmark
Alliances with market leaders – Therapeutics
    Table 19: Alliances, acquisitions and mergers in the field of epigenetics since 2007
    Table 20: Areas of focus for companies developing diagnostic tests based on epigenetics
  Asuragen Inc, Austin, TX
  Epigenomics AG, Berlin, Germany
  Exiqon, Copenhagen, Denmark
  OncoMethylome Sciences, Durham, NC
  Orion Genomics, Saint Louis, MO
  Rosetta Genomics, Rehovot, Israel
Alliances with market leaders – Diagnostics
Conclusion

CHAPTER 6 - OUTLOOK & FUTURE OF EPIGENETIC RESEARCH

Executive Summary

OUTLOOK & FUTURE OF EPIGENETIC RESEARCH
Epigenetics research now
  Figure 10: Progress in epigenetics related therapeutics and diagnostics over the next 5 years
Therapeutic launches and new indications over the next 5 years
  Table 21: Revenues generated by Vidaza, Dacogen and Zolinza in 2009
New combinations and a changing therapeutic paradigm in cancer
  Table 22: Examples of clinical trials of combinations of DNMTi, HDACi and chemotherapy
  Table 23: Examples of clinical trials of drug combinations including panobinostat
New diagnostic products
  Table 24: New diagnostic products identifying epigenetic biomarkers that will be launched to the market over the next few years
Next generation sequencing
Epigenetics research in 5 to 10 years time
  Figure 11: Progress in epigenetics related therapeutics and diagnostics over the next 5 to 10 years
Therapeutic launches
Therapeutics and companion diagnostics for novel epigenetic targets
Epigenetics research more than 10 years from now
  Figure 12: Progress in epigenetics-related therapeutics and diagnostics 10 years +
Conclusions

Glossary
Biography of the author
References
Endnotes
Skip to top


Ask Your Question

Epigenetics: Current and future applications that are driving novel drug discovery
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: